Our Partners
About US
Welcome to
CellServe GmbH
Diseases of the heart are still the main cause of death in western industrial nations. In Germany, a total of about 50,000 people die each year from cardiac insufficiency.
We use novel specialised cells from the patient’s heart biopsies to treat severe heart muscle weakness in a natural way and to improve the patient’s quality of life.
Our innovative cell therapy development focuses specifically on strengthening the heart muscle and the natural healing processes in the heart.
Our Vision
Prolong life and improve the quality of life
To provide the first curative, alternative therapy (rather than just treating symptoms) with the goal to prolong life and improve the quality of life of patients with heart failure
OUR Mission
Affordable and less invasive
To market cardiac-derived cell therapy as an affordable and less invasive therapy than heart transplantation.
The Project
Explore our innovative project
CardAPcells
Cardiac-derived Adherent Proliferating (CardAPcells): Proprietary novel cells derived from heart tissue for therapy of chronic myocardial insufficiency
Product strategy
A 2nd generation product cells brings immense upside potential and enables manufacturing of large quantities, thus improving scalability
How it works
CardAPcells are cultivated using the patients‘ own cells: Cells derived from heart tissue for the novel proprietary therapy of chronic myocardial tissue
Jasmin Nezirevic | Managing Partner
Prometheus Venture Advisors GmbH
Contact
CellServe GmbH
Charitéplatz 1, internal: Virchowweg 11
10117 Berlin
Germany
gf@cellserve.de